Victory Capital Management’s GeneDx Holdings WGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.08M Buy
63,505
+36,530
+135% +$3.33M ﹤0.01% 1388
2025
Q4
$3.51M Sell
26,975
-49,157
-65% -$6.75M ﹤0.01% 1429
2025
Q3
$8.2M Buy
76,132
+51,347
+207% +$5.59M ﹤0.01% 1174
2025
Q2
$2.29M Buy
24,785
+9,120
+58% +$716K ﹤0.01% 1549
2025
Q1
$1.39M Buy
15,665
+12,945
+476% +$1.12M ﹤0.01% 1655
2024
Q4
$209K Buy
+2,720
New +$190K ﹤0.01% 2222
2023
Q3
Sell
-11,617
Closed -$69.2K 2561
2023
Q2
$69.2K Buy
11,617
+1,238
+12% +$9.8K ﹤0.01% 2352
2023
Q1
$125K Buy
10,379
+9,816
+1,744% +$131K ﹤0.01% 2327
2022
Q4
$4.9K Hold
563
﹤0.01% 2567
2022
Q3
$16K Sell
563
-449
-44% -$20.6K ﹤0.01% 2640
2022
Q2
$42K Buy
1,012
+357
+55% +$24.2K ﹤0.01% 2566
2022
Q1
$46K Buy
655
+315
+93% +$35K ﹤0.01% 2602
2021
Q4
$50K Sell
340
-9
-3% -$2.01K ﹤0.01% 2642
2021
Q3
$88K Buy
+349
New +$120K ﹤0.01% 2631

Other funds holding WGS

Victory Capital Management's WGS Position: Q1 2026 in Review

Victory Capital Management increased its GeneDx Holdings (WGS) stake by 135% in Q1 2026, buying an estimated $3.33M and bringing the position to 63,505 shares worth $4.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1388.

Victory Capital Management first reported a position in WGS in Q3 2021 and has held it in 14 quarters since. The position peaked at $8.2M in Q3 2025. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

  • Victory Capital Management held 63,505 shares of GeneDx Holdings worth $4.08M as of Q1 2026.
  • Victory Capital Management bought 36,530 GeneDx Holdings shares in Q1 2026, an estimated $3.33M.
  • GeneDx Holdings made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1388 holding.
  • Victory Capital Management first reported a position in GeneDx Holdings in Q3 2021 and has held it in 14 quarters since.
  • Victory Capital Management's GeneDx Holdings position peaked at $8.2M in Q3 2025.
  • 240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.